Non-competitive immunoassay for small analytes using phage display
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing non-competitive immunoassays for small analytes has been challenging due to difficulties in producing secondary anti-immune complex antibodies, which are self-antigens and prone to breakdown, limiting the sensitivity and specificity of existing assays.
Innovation Solution
Utilizing a display recombinant binding partner library to select and obtain anti-IC antibodies, bypassing the need for animal immunization, and employing phage display technology to enrich and sequence binding partners for use in a non-competitive immunoassay format, enabling a homogenous and cost-effective detection method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional animal immunization is used to produce anti-IC antibodies, then the assay can be developed, but the antibodies are self-antigens and prone to breakdown, reducing reliability
Solution Approach 1:
The patent uses phage display technology to create a library of recombinant antibodies that copy and replicate the desired binding specificity without requiring animal immunization. The phage display system allows systematic generation and selection of anti-IC antibodies that bind to immune complexes formed by primary antibodies and small analytes, providing stable, reproducible reagents without the self-antigen problems of conventional immunization
Solution Approach 2:
The patent replaces the biological immunization process (involving animal hosts, adjuvants, and immune response) with a molecular biology-based phage display system. This substitution allows direct manipulation and selection of antibody genes encoding specific binding partners, eliminating the need for animal immunization and the associated reliability issues with self-antigen recognition
2Reliability
If phage display technology is used to select binding partners, then the assay becomes more reliable and rapid, but the device complexity increases
Solution Approach 1:
The patent segments the antibody function into discrete components: the phage display system generates individual antibody clones, each binding to specific epitopes on the immune complex. This segmentation allows systematic evaluation and selection of optimal binding partners without requiring the entire complex immunization process, improving reliability while managing complexity through modular approach
Solution Approach 2:
The patent performs preliminary selection of binding partners using phage display technology before final assay development. By pre-selecting and characterizing anti-IC antibodies with high specificity for immune complexes, the system establishes reliable reagents in advance, reducing the need for complex iterative optimization during assay development
3Productivity
If non-competitive immunoassay format is used for small analytes, then sensitivity and speed are improved, but the difficulty of producing secondary antibodies limits applicability
Solution Approach 1:
The patent uses phage display to generate multiple clones of anti-IC antibodies with different specificities and affinities. This copying approach provides a diverse library of potential secondary reagents that can be selected based on assay requirements, enabling rapid development of non-competitive immunoassays for small analytes without being limited by the scarcity of naturally occurring anti-IC antibodies
Solution Approach 2:
The patent systematically varies parameters such as antibody affinity, specificity, and binding kinetics through phage display library construction. By controlling these parameters during the selection process, the system optimizes the performance of non-competitive immunoassays for small analytes, achieving high sensitivity and speed while ensuring reliable production of secondary reagents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for rapid, reliable, and sensitive detection of small analytes, such as drugs and hormones, with improved specificity and simplicity, suitable for on-site testing and applicable to various clinical and environmental analyses.
Implementation Method 1
a first binding partner that binds to the analyte
Implementation Method 2
a second binding partner that binds to the complex of the analyte and the first binding partner
Data Source
AI summary
A non-competitive immunoassay for small analytes, wherein the analyte is reacted with two binding partners. The first binding partner binds to the analyte to form a complex between the first binding partner and the analyte, and the second binding partner binds to the complex formed by the first binding partner and the analyte. The resulting complex formed between the analyte and the binding partners is detected. The binding partners are proteins, such as antibodies including antibody fragments.